Applied Molecular Transport Inc.
Applied Molecular Transport Inc. (AMTI): 2 pipeline candidates · ~13 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.5 months
D/E 0.23 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Applied Molecular Transport Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$18.1M
Quarterly Burn
$4.4M
Runway
12.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Applied Molecular Transport Inc.'s pipeline?
Applied Molecular Transport Inc. (AMTI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Applied Molecular Transport Inc.'s lead drug candidate?
Applied Molecular Transport Inc.'s most advanced tracked candidate is amt-101 (Phase 2) for Chronic pouchitis, rheumatoid arthritis (RA).
What is Applied Molecular Transport Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Applied Molecular Transport Inc. has approximately 12.5 months of cash runway.
Who is the CEO of Applied Molecular Transport Inc.?
Shawn Cross is the chief executive officer of Applied Molecular Transport Inc. (AMTI).
Get the full picture on Applied Molecular Transport Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.